Patents by Inventor David L. Pompliano

David L. Pompliano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5891621
    Abstract: An in vitro screening assay which identifies enzyme inhibitors and allows for the simultaneous assay of many enzymes. Enzyme, substrate, co-factor, etc. concentrations are optimized so that inhibitors of any one of the enzymes in the pathway are equally likely to be detected. Necessarily, the flux of substrate through each enzyme should be nearly the same during the assay, i.e., each of the enzyme catalyzed steps must be equally rate-limiting. Preferably, optimal assay conditions are predicted by computer modeling. Further, the pathway conditions are optimized through variation of enzyme, starting substrate, co-substrate and co-factor concentrations. A positive response is initially detected as a change in the amount of the product generated at the end of the enzyme cascade as compared to a standard. A sample producing a positive result can be deconvoluted.
    Type: Grant
    Filed: September 24, 1997
    Date of Patent: April 6, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Renee M. Chabin, David W. Kuo, John F. O'Connell, David L. Pompliano, Kenny K. Wong
  • Patent number: 5525479
    Abstract: This invention is directed to a continuous fluorescence assay of Ras farnesyl:protein transferase. This assay can be used to screen for inhibitors of farnesyl:protein transferase. The assay may also be modified to screen for inhibitors of other protein transferases.
    Type: Grant
    Filed: February 17, 1994
    Date of Patent: June 11, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Neville J. Anthony, David L. Pompliano
  • Patent number: 5474921
    Abstract: The present invention is directed to an assay which is used to determine the inhibitory activity of a test compound against a particular phosphoinositide-specific phospholipase C enzyme, that enzyme being phospholipase C.gamma.. The present invention is also directed to the preparation of phospholipase C.gamma. by recombinant expression in a bacterial cell and isolation of the expressed enzyme.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: December 12, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth S. Koblan, David L. Pompliano